Alpha 1‐antitrypsin: A novel tumor‐associated antigen identified in patients with early‐stage breast cancer
- 23 July 2012
- journal article
- research article
- Published by Wiley in Electrophoresis
- Vol. 33 (14) , 2130-2137
Abstract
Several studies have demonstrated that sera from patients with cancer contain antibodies that recognize a unique group of autologous antigens called tumor‐associated antigens (TAA). In the current study, we employed an immunoproteomic approach, combining 2DE, Western blot, and MALDI‐MS to identify TAA in the sera of patients diagnosed with infiltrating ductal or in situ carcinoma breast cancer. Sera obtained from 25 newly diagnosed patients with stage II breast cancer and 20 healthy volunteers was evaluated for the presence of novel TAA. Alpha 1‐antitrypsin (A1AT) antibodies were detected in 24 of 25 patients with breast cancer (96%) and in 2 of 20 controls (10%). Sensitivity of detection of autoantibodies against A1AT in patients with breast cancer was 96%. Our preliminary results suggest that A1AT and autoantibodies against alpha 1 antitrypsin may be useful serum biomarkers for early‐stage breast cancer screening and diagnosis.Keywords
This publication has 33 references indexed in Scilit:
- Novel Proteomic Strategy Reveal Combined α1 Antitrypsin and Cathepsin D as Biomarkers for Colorectal Cancer Early ScreeningJournal of Proteome Research, 2010
- Characteristics of hepatocellular carcinoma in a murine model of alpha‐1‐antitrypsin deficiencyHepatology Research, 2010
- RETRACTED: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancerGynecologic Oncology, 2009
- Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysisElectrophoresis, 2009
- Using Proteomic Approach to Identify Tumor-Associated Antigens as Markers in Hepatocellular CarcinomaJournal of Proteome Research, 2008
- Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomesAnnals of Oncology, 2007
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Human body fluid proteome analysisProteomics, 2006
- Peroxiredoxin‐I is an autoimmunogenic tumor antigen in non‐small cell lung cancerFEBS Letters, 2005
- Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumoursEuropean Journal of Cancer, 1996